Phase II trial demonstrates activity of durvalumab in patients with recurrent or metastatic head and neck cancer
Summary
Potential limitations with this type of immunotherapy, however, include the possibility that patients will not respond to treatment and/or that they may experience treatment-related side effects if the immune system also mistakenly targets healthy cells.For immunotherapy to increase its clinical utility, its important that we can better identify the patients who will most likely respond to treatment," said Lillian Siu, MD, lead author of the study, as well as a senior medical oncologist at Princess Margaret Cancer Centre and a professor of medicine at the University of Toronto.Our results add to the body of evidence that this immune checkpoint inhibitor is tolerable and has demonstrated encouraging clinical activity across a range of tumors, including in heavily pre-treated recurrent or metastatic head and neck cancer."The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy.Related Links SCOTTSDALE, Ariz., Feb. 13, 2018 /PRNewswire-USNewswire/ -- Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow growth in tumors with low or negative expression of the PD-L1 protein.
Classifications
AskAI Classifications
LabelsLinked Companies
